Vaxcyte Inc

PCVX

Equity

ISIN null / Valor 54991636

NASDAQ (2026-02-19)

USD 57.32+2.05%

Vaxcyte Inc
UMushroom community rating:

3.00 2 votes No rating yet

NegativeNeutralPositive

About company

Vaxcyte Inc is a biotechnology company focused on developing vaccines to address infectious diseases. Their primary focus is on improving existing pneumococcal vaccines to combat invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance, and meningitis. The company is currently working on developing a 31-valent pneumococcal conjugate vaccine candidate, VAX-31, following their VAX-24 vaccine. In addition to their pneumococcal vaccine franchise, Vaxcyte is also working on vaccine candidates targeting Group A Strep, periodontitis, and Shigella in preclinical development.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-31.2%1Y

29.6%3Y

122%5Y

Performance

84.0%1Y

61.5%3Y

65.4%5Y

Volatility

7504 M

Market cap (USD)

1,167,536

Daily traded volume (Shares)

82.17 / 80.1

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.00

2 votes

Performance:

2.50

Innovation:

3.50

Society:

4.00

Nature:

3.50

****** Panggabean

United Kingdom, 25 Oct 2025

Vaxcyte is doing impressive vaccine research and has strong funding, but it’s still in the testing stage and losing money. The science is promising, yet the stock has been volatile, showing investors are waiting for real commercial results before getting confident again.